Eli Lilly Acquires Kelonia Therapeutics in 7 Billion Dollar Deal

Eli Lilly has announced an agreement to acquire biotech firm Kelonia Therapeutics in a transaction valued at up to $7 billion. According to Crunchbase News, this acquisition represents the largest purchase of a venture-backed biotech company in years.  

Kelonia has developed a proprietary in vivo gene placement system (iGPS ) that uses specially engineered lentiviral-based particles designed to efficiently and selectively enter T-cells inside the body, allowing the patient's own body to generate chimeric antigen receptor T-cell (CAR-T) therapies that can treat underlying disease. 

According to Towards Healthcare, the U.S. Cell and Gene Therapy Market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 4.74 billion in 2026 to approximately USD 20 billion by 2035, representing a compound annual growth rate (CAGR) of 17.2% from 2026 to 2035. Growth is driven by the increasing demand for personalised therapies, significant investments in R&D, and a rising number of clinical trials. It is broadening beyond oncology to include treatments for genetic disorders, cardiovascular diseases, and neurological conditions, reflecting the versatility of cell and gene therapies and their potential to address a wide range of diseases with unmet medical needs. 

Rising Trend in In Vivo Therapeutics Acquisitions 

According to Crunchbase News, Lilly purchased Orna Therapeutics, another company focused on engineering immune cells in vivo, in a deal valued at up to $2.4 billion just two months ago, and shows a pattern of high valuations for startups in in vivo therapeutics. 

President of Lilly Oncology and head of corporate business development, Jacob Van Naarden, said It's an intravenously delivered therapy, one time. He even explained that the new approach simplifies the treatment process significantly. The acquisition aims to move cell therapy beyond specialised academic medical centres. 

About Kelonia Therapeutics  

Kelonia’s iGPS in vivo gene delivery platform uses potent lentiviral vector-like particles to deliver genetic cargo efficiently and selectively to the desired tissue. This approach is designed to maximise therapeutic impact while minimising off-target effects, enabling the development of transformational therapies for solid tumours, hematologic cancers, and immune-related conditions.  

The company focuses on developing genetic medicines for cancer, autoimmune, and inflammatory diseases, leveraging its proprietary gene delivery technology to precisely target specific tissues and cells, primarily T cells, for therapeutic purposes.  

A recent report by Towards Healthcare highlights that the U.S. Cell and Gene Therapy Market is witnessing growth due to advancements in biotechnology, increasing investments in advanced biologics, and a growing biotechnology ecosystem. The FDA's regulatory frameworks, including accelerated approval pathways and RMAT designations, are accelerating the development and commercialisation of cell and gene therapies. 

North America is dominated by holding the largest share of revenue, with a strong clinical trial landscape, and favourable regulatory frameworks contribute to its leadership in the field. Asia Pacific is anticipated to drive the market's growth, due to the increasing prevalence of genetic disorders and the demand for personalised medicine.